Refractory Childhood Epilepsy Clinical Trial
— LEVEMADOfficial title:
Modified Atkins Diet Versus Levetiracetam for Refractory Epilepsy in Children: A Randomized Open-Label Study
In this study, the efficacy of add-on modified Atkins diet will be compared with add-on Levetiracetam in children with refractory epilepsy in a randomized open label trial. The results will aid clinicians in deciding the treatment options when a child has been diagnosed to have refractory epilepsy.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | April 20, 2021 |
Est. primary completion date | March 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 12 Years |
Eligibility |
Inclusion Criteria: Seizures persisting more than 3 per week despite the use of at least 2 appropriate anti-epileptic drugs in appropriate doses - Exclusion Criteria: 1. Known or suspected inborn error of metabolism 2. Surgically remediable causes of epilepsy such as tumours, cortical dysplasia, mesial temporal lobe epilepsy etc with refractory focal epilepsy. 3. Prior use of the ketogenic or modified Atkins diet or levetiracetam. 4. Systemic illness- chronic hepatic, renal or pulmonary disease 5. Prior history of depression or severe behavioural problems. - |
Country | Name | City | State |
---|---|---|---|
India | Lady Hardinge Medical College | New Delhi | Delhi |
Lead Sponsor | Collaborator |
---|---|
Lady Hardinge Medical College |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy in reducing seizures measured by The proportion of responders, i.e., patients who achieve > 50% seizure reduction from the baseline in the modified Atkins diet group at 3 months in comparison to the levetiracetam group. | The proportion of responders, i.e., patients who achieve > 50% seizure reduction from the baseline in the modified Atkins diet group at 3 months in comparison to the levetiracetam group. | 3 months | |
Secondary | Treatment emergent adverse effects in both groups | Tolerability and the adverse effects of the modified Atkins diet and levetiracetam | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00836836 -
Modified Atkins Diet in Childhood Epilepsy
|
Phase 2/Phase 3 | |
No longer available |
NCT02556008 -
Cannabidiol for Pediatric Epilepsy (Compassionate Use)
|
N/A |